Literature DB >> 7804440

Exaggerated blood pressure response to angiotensin II in patients with Cushing's syndrome due to adrenocortical adenoma.

G Yasuda1, H Shionoiri, S Umemura, I Takasaki, M Ishii.   

Abstract

We studied the roles played by the renin-angiotensin system in inducing hypertension in nine patients with Cushing's syndrome (CS) resulting from adrenocortical adenoma, and compared them with those in patients with primary aldosteronism (PA), renovascular hypertension (RVH) and essential hypertension (EH). In the CS group, each parameter, including serum potassium, plasma renin activity, plasma aldosterone, deoxycorticosterone and corticosterone concentrations, is within the normal range. However, plasma renin activity in the CS group was lower than that in the RVH group but higher than that in the PA group, and plasma aldosterone concentration was lower than that in each RVH or PA group. These findings indicated that the CS group had a different type of hypertension from that in either RVH or PA, in which the renin angiotensin system or mineralocorticoids play an important role in hypertension. Meanwhile, captopril (50 mg) administration either with or without indomethacin pretreatment decreased the mean blood pressure in the CS group, although captopril failed to change it in the PA group or in normal subjects. Furthermore, the pressor response to exogenous angiotensin II in the CS group was higher than that in the RVH or EH group, but was not different from that in the PA group. Thus, the hypertension in patients with CS due to adrenocortical adenoma appears to be mediated through a change in the renin-angiotensin system in the form of exaggerated pressor responses to angiotensin II.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7804440     DOI: 10.1530/eje.0.1310582

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  4 in total

Review 1.  Cardiovascular risk and mortality in patients with active and treated hypercortisolism.

Authors:  Dingfeng Li; Omar M El Kawkgi; Andres F Henriquez; Irina Bancos
Journal:  Gland Surg       Date:  2020-02

Review 2.  The hypertension of Cushing's syndrome: controversies in the pathophysiology and focus on cardiovascular complications.

Authors:  Andrea M Isidori; Chiara Graziadio; Rosa Maria Paragliola; Alessia Cozzolino; Alberto G Ambrogio; Annamaria Colao; Salvatore M Corsello; Rosario Pivonello
Journal:  J Hypertens       Date:  2015-01       Impact factor: 4.844

3.  Demystifying "Steroid Withdrawal" During Remission in Cushing's Disease: Is Mineralocorticoid Replacement the Answer?

Authors:  Nimisha Jain; K Mahesh Kumar; Naresh Sachdeva; Anil Bhansali; Rama Walia
Journal:  Indian J Endocrinol Metab       Date:  2019 Jul-Aug

4.  Cushing's Disease: Assessment of Early Cardiovascular Hemodynamic Dysfunction With Impedance Cardiography.

Authors:  Agnieszka Jurek; Paweł Krzesiński; Grzegorz Gielerak; Przemysław Witek; Grzegorz Zieliński; Anna Kazimierczak; Robert Wierzbowski; Małgorzata Banak; Beata Uziębło-Życzkowska
Journal:  Front Endocrinol (Lausanne)       Date:  2021-10-01       Impact factor: 5.555

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.